All In Biotech

Drug Trial Radar · NCT05671029

Thorough QT/QTc of Pritelivir in Healthy Subjects

A Double-blind, Single-center, Randomized, Placebo- and Positive-controlled, Parallel-group Trial With a Nested Crossover Part on the Electrocardiographic Effects 100 and 400 mg Pritelivir Per Day in Healthy Subjects: a Thorough QT/QTc Trial

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Dec 4, 2022

Primary completion

May 18, 2023

Study completion May 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 clinical trial was a double-blind, single-center, randomized and placebo-controlled trial in which healthy male and female subjects received in 2 parallel-groups daily oral doses of pritelivir (Group 1) or matching placebo (Group 2). Within Group 2, a single oral administration of moxifloxacin (positive control) and corresponding matching placebo was administered in a 2-sequence crossover design (nested crossover).

Conditions

  • Healthy Subjects

Interventions

  • Pritelivir and moxifloxacin placeboDrug

    oral administration

  • Pritelivir placebo, moxifloxacin and moxifloxacin placeboDrug

    oral administration

  • Pritelivir placebo, moxifloxacin placebo and moxifloxacinDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of Pritelivir on the QTcF Interval (QTc Using Fridericia Correction Method) in Comparison With Placebo in Male and Female Subjects.Time frame: Day -2 to Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond Pharmacology Ltd

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.